Get started
Author

Juan Gonzalez‐Maffe

Observed names: Gonzalez Maffe, Juan, Gonzalez-Maffe, Juan Guillermo, J. Gonzalez-Maffe, Juan Gonzalez-Maffe
ORCID: 0000-0002-7341-3813
Observed ORCID: 0000-0002-7341-3813
OpenAlex ID: A5014882103
Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women
2014 · Rufus Cartwright, Anna C. Kirby, et al. · American Journal of Obstetrics and Gynecology · 101
PDF
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2021 · Caroline Even, Hung-Ming Wang, et al. · Clinical Cancer Research · 62
PDF
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
2023 · S. Piperno-Neumann, M. S. Carlino, et al. · British Journal of Cancer · 60
PDF
Systematic Review and Meta-analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in Men
2014 · Rufus Cartwright, Altaf Mangera, et al. · European Urology · 36
PDF
Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma
2019 · Ellen Kapiteijn, Matteo Carlino, et al. · Cancer Research · 22
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment
2016 · Alexina J. Mason, Juan Gonzalez-Maffe, et al. · Statistics in Medicine · 10
PDF
Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis
2019 · Norbert Hollaender, Juan Gonzalez‐Maffe, et al. · Biometrical Journal · 4
Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma
2019 · Ellen Kapiteijn, Matteo Carlino, et al. · Clinical Trials · 2
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Data from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Data from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 4 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Works count: 32
Citation count: 297
H-index: 6
I10-index: 6
Year
Topic
Type